News
AstraZeneca enters cholesterol drug delivery collaboration with biotech start-up

Multinational pharmaceutical company AstraZeneca has teamed up with ‘young’ Chinese biotech Cholesgen to develop new drugs to target high cholesterol and related metabolic diseases.
The three-year collaboration will see Shanghai-based Cholesgen receive an initial payment and a pre-defined license package for each qualified drug candidate nominated by UK-headquartered AstraZeneca to progress into clinical development.
The joint research effort will leverage complementary strengths and focus on selected targets from Cholesgen’s early-stage portfolios.
The programme will start from first-in-class targets and mechanisms originally identified by Chinese researchers as the scientists from AstraZeneca and Cholesgen work to deliver novel medicines to tackle hypercholesterolemia – a term used to describe high blood cholesterol levels – which is a major risk factor for developing atherosclerotic cardiovascular disease (ASCVD).
Hypercholesterolemia is currently treated by lifestyle changes, such as diet, exercise, and quitting smoking, as well as pharmacological options including statins, bile acid sequestrants, fibrates, and cholesterol absorption inhibitors.
But ASCVD remains a leading cause of death globally, despite advances in preventative care.
It is caused by fatty deposits building up in the arteries, with both high blood pressure and high cholesterol increasing the risk of developing the common condition, which is most likely to affect the over-65s.
ASCVD provokes the narrowing of the arteries, making it difficult for blood to flow through them, increasing a person’s risk of suffering a heart attack or stroke.
There is a need for novel treatments to tackle hypercholesterolemia, however, as millions of people can’t or won’t take the first-choice treatment for high cholesterol – statins – because of side effects.

Sir Menelas Pangalos
British neuroscientist Sir Menelas Pangalos, executive vice president of BioPharmaceuticals Research and Development at AstraZeneca, has stressed the importance of the alliance and licensing agreement with Cholesgen.
He said: “This is an important collaboration for AstraZeneca, led by deep scientific expertise and a shared ambition to address the key drivers that contribute to hypercholesterolemia and related metabolic diseases. We look forward to working together to accelerate target discovery and preclinical research in this area of high unmet need.”
Leading cholesterol metabolism researcher Dr Bao-Ling Song, who founded Cholesgen in 2021 and is also the biotech’s chair, added: “As a young biotech with deep understanding of target biology and a focused pipeline, Cholesgen is thrilled to start this strategic collaboration with AstraZeneca and hopes to accelerate the delivery of innovative medicines for patients with hypercholesterolemia or related metabolic diseases.”
Cholesgen recently raised $14.1m in a Series A financing round. Backers included AZ-CICC Medical Fund, a joint investment trust established by AztraZeneca and financial services company China International Capital Corporation.
Since launching in February 2021, Cholesgen has made great strides in its mission to develop innovative therapeutic solutions for cholesterol-related diseases, such as hyperlipidemia, obesity, atherosclerosis, and non-alcoholic steatohepatitis.
For AstraZeneca, the link-up with Cholesgen marks a return to working on successfully tackle hypercholesterolemia after last September calling time on its Ionis Pharmaceuticals-partnered cholesterol drug ION449.
AstraZeneca had licensed the asset in 2015. But despite the antisense therapy hitting its primary endpoint of reducing low-density lipoprotein cholesterol in a phase 2b trial, the results fell short of AstraZeneca’s efficacy criteria and the company opted against moving the candidate into phase 3.
News
Gut-friendly foods may damage heart, charity warns
News
Diabetes patients face increased risk of undiagnosed heart failure

People with diabetes may have undiagnosed heart failure that could be detected by a simple screening blood test, research suggests.
The TARTAN-HF trial found that one in four patients with diabetes who had at least one other risk factor for heart failure had undiagnosed heart failure detected through screening with a blood test and ultrasound scanning of the heart.
Experts said the findings show the extent of unrecognised heart failure in people with diabetes, and how the condition can be detected using a widely available blood test called NT-proBNP, which measures how much strain the heart is under.
They suggest a heart failure screening programme for diabetics could improve diagnosis rates, lead to earlier treatment and potentially reduce the risk of hospitalisation and death.
The study, involving 700 patients, was led by the University of Glasgow in collaboration with AstraZeneca, Roche Diagnostics, Us2.ai, NHS Greater Glasgow and Clyde and NHS Lanarkshire.
Dr Kieran Docherty, clinical senior lecturer at the University of Glasgow’s School of Cardiovascular and Metabolic Health, said: “Our results from the landmark TARTAN-HF trial identified heart failure in a large proportion of people living with diabetes, emphasising the need for a heart failure screening strategy in this group of patients.
“We know that many of the symptoms and signs of heart failure are non-specific, and may go unrecognised as potentially being due to heart failure for a long time.
“The strategy used in our trial is simple and easy to implement in clinical practice, and will aid in the early identification of heart failure in people with diabetes, and facilitate the initiation of medications that we know improve outcomes in patients with heart failure.”
The study, which began more than three years ago, involved more than 700 people with diabetes from the two health board areas who had at least one other risk factor for heart failure.
They were randomly assigned either to receive heart failure screening or to continue with their usual care.
Researchers found screening uncovered a large number of previously unrecognised cases of heart failure. Around one in four, or 24.9 per cent, of those screened were found to have the condition within six months, compared with 1 per cent in the group continuing their usual care.
The study, involving patients with type 1 and type 2 diabetes, found almost all of the participants found to have heart failure had preserved ejection fraction, which can be difficult to detect without dedicated testing.
The findings of the TARTAN-HF trial were presented at the American College of Cardiology conference taking place from 28 to 30 March in New Orleans in the US.
Dr Edward Piper, medical director at AstraZeneca UK, said: “Delayed diagnosis and treatment of heart failure in people with type 2 diabetes contributes to poor long-term outcomes. TARTAN-HF demonstrates that targeted, risk-based screening can identify previously undiagnosed heart failure in approximately one in four high-risk patients with diabetes, enabling earlier intervention with guideline-directed therapy.”
Dr Christian Simon, head of global medical affairs at Roche Diagnostics, said: “We are proud to have supported the landmark TARTAN-HF trial. These findings demonstrate the transformative power of early, accessible diagnostics like the NT-proBNP blood test.
“By identifying unrecognised heart failure in people with diabetes, we enable clinicians to initiate appropriate treatments sooner, ultimately improving patient outcomes and lives.”
News
UK government announces £6.3m fund to boost men’s health

The UK has launched a £6.3m men’s health fund to back local projects aimed at helping men and boys live longer, healthier lives.
The Men’s Health Community Fund is a partnership between the Department of Health and Social Care, Movember and People’s Health Trust.
The government is contributing £3m, while the two charities are more than doubling that to take the total to £6.3m.
Grants will support community projects reaching underserved men and boys aged 16 and over, particularly in the most disadvantaged areas and at key points in their lives such as becoming a father, losing a job or retiring.
Projects could include support for new fathers, activities for men facing loneliness and social isolation, services to help young men engage with the health system, and support for men in work, out of work and moving into retirement.
The programme will bring together voluntary, community and social enterprise organisations to test new ways of reaching men who are least likely to use traditional health services.
An evaluation funded through the National Institute for Health and Care Research will assess what works and help inform future policy and delivery.
Health and social care secretary Wes Streeting said: “Too many men across the country are living shorter, less healthy lives, particularly those in our most disadvantaged communities.
“This new partnership will help men get the support they need in the places they feel most comfortable, their communities, among people they trust.
“By working with expert charities and local organisations, we can reach the men who are too often missed by traditional services and help them take better care of their mental and physical health.”
“It is a key step in delivering our first ever Men’s Health Strategy and driving forward our ambition to halve the gap in healthy life expectancy between the richest and poorest areas.”
The Men’s Health Strategy sets out plans to tackle the physical and mental health challenges men and boys face.
Men can be less likely to seek help and more likely to suffer in silence, while higher rates of smoking, drinking, gambling and drug use are damaging men’s health and affecting families, workplaces and communities.
The government is also investing £3.6m over the next three years in suicide prevention projects for middle-aged men in local communities across areas of England where men are most at risk, many of which are also among the most deprived. Suicide is one of the biggest killers of men under 50, and three-quarters of all suicides are men.
The projects will aim to break down barriers middle-aged men face in seeking support, including stigma around asking for help and a lack of awareness of what is available and how to access it.
They will be co-designed with experts and men with lived experience of mental health crises and suicidal thoughts.
News4 weeks agoAtrogi starts muscle-preserving drug trial
News4 weeks agoLandmark prostate cancer screening trial begins in UK
News4 weeks agoNHS to review cost effectiveness of new Alzheimer’s drugs
News4 weeks agoCentenarian study probes healthy ageing
News4 weeks agoActive sitting linked to lower dementia risk
News4 weeks agoEndogenex raises US$50m for diabetes procedure
News4 weeks agoWorking nights undermines type 2 diabetes management – study
News4 weeks agoUK government announces £6.3m fund to boost men’s health


















